

Alberto Broniscer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2225037/publications.pdf>

Version: 2024-02-01

106
papers

7,206
citations

87888

38
h-index

60623

81
g-index

110
all docs

110
docs citations

110
times ranked

7477
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. <i>Nature Genetics</i> , 2012, 44, 251-253.	21.4	1,402
2	The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. <i>Nature Genetics</i> , 2014, 46, 444-450.	21.4	871
3	Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease. <i>Journal of Clinical Oncology</i> , 2010, 28, 3061-3068.	1.6	558
4	Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine Glioma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3999-4006.	1.6	286
5	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	1.6	250
6	Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in Children. <i>Journal of Clinical Oncology</i> , 2007, 25, 682-689.	1.6	200
7	Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist. <i>Oncologist</i> , 2004, 9, 197-206.	3.7	199
8	Novel Oncogenic <i>PDGFRA</i> Mutations in Pediatric High-Grade Gliomas. <i>Cancer Research</i> , 2013, 73, 6219-6229.	0.9	189
9	Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. <i>Clinical Cancer Research</i> , 2019, 25, 7303-7311.	7.0	128
10	A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor Consortium. <i>Neuro-Oncology</i> , 2011, 13, 290-297.	1.2	110
11	Common variants in <i>ACYP2</i> influence susceptibility to cisplatin-induced hearing loss. <i>Nature Genetics</i> , 2015, 47, 263-266.	21.4	109
12	Phase I Study of Vandetanib During and After Radiotherapy in Children With Diffuse Intrinsic Pontine Glioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4762-4768.	1.6	108
13	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	1.6	106
14	Second neoplasms in pediatric patients with primary central nervous system tumors. <i>Cancer</i> , 2004, 100, 2246-2252.	4.1	101
15	Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children. <i>Cancer</i> , 2005, 103, 133-139.	4.1	101
16	Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420. <i>Clinical Cancer Research</i> , 2007, 13, 1511-1515.	7.0	89
17	H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. <i>Acta Neuropathologica</i> , 2019, 137, 637-655.	7.7	85
18	Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2013, 19, 3050-3058.	7.0	82

#	ARTICLE	IF	CITATIONS
19	Temozolomide after Radiotherapy for Newly Diagnosed High-grade Glioma and Unfavorable Low-grade Glioma in Children. <i>Journal of Neuro-Oncology</i> , 2006, 76, 313-319.	2.9	76
20	Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. <i>Neuro-Oncology</i> , 2011, 13, 298-306.	1.2	76
21	Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. <i>Cancer</i> , 2010, 116, 4632-4637.	4.1	70
22	Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3137-3143.	1.6	67
23	Radiation Therapy and High-Dose Tamoxifen in the Treatment of Patients With Diffuse Brainstem Gliomas: Results of a Brazilian Cooperative Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 1246-1253.	1.6	64
24	Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma. <i>Clinical Cancer Research</i> , 2009, 15, 701-707.	7.0	64
25	A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7294-7302.	7.0	63
26	Phase I Trial of Single-Dose Temozolomide and Continuous Administration of <i>O</i> ⁶ -Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report. <i>Clinical Cancer Research</i> , 2007, 13, 6712-6718.	7.0	62
27	Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. <i>Neuro-Oncology</i> , 2014, 16, 848-855.	1.2	62
28	A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. <i>European Journal of Cancer</i> , 2010, 46, 3287-3293.	2.8	59
29	Three-dimensional susceptibility-weighted imaging and two-dimensional T2*-weighted gradient-echo imaging of intratumoral hemorrhages in pediatric diffuse intrinsic pontine glioma. <i>Neuroradiology</i> , 2010, 52, 1167-1177.	2.2	57
30	Young age may predict a better outcome for children with diffuse pontine glioma. <i>Cancer</i> , 2008, 113, 566-572.	4.1	54
31	A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2020, 22, 875-885.	1.2	53
32	Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. <i>Acta Neuropathologica</i> , 2020, 139, 1071-1088.	7.7	50
33	Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2013, 114, 339-344.	2.9	48
34	Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. <i>Neuro-Oncology</i> , 2008, 10, 341-347.	1.2	46
35	Survival and Late Mortality in Long-Term Survivors of Pediatric CNS Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 1532-1538.	1.6	45
36	Pediatric low-grade gliomas and the need for new options for therapy: why and how?. <i>Cancer Biology and Therapy</i> , 2009, 8, 4-10.	3.4	45

#	ARTICLE	IF	CITATIONS
37	Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy. <i>Neuro-Oncology</i> , 2015, 17, 448-456.	1.2	44
38	Brain Stem Involvement in Children with Neurofibromatosis Type 1: Role of Magnetic Resonance Imaging and Spectroscopy in the Distinction from Diffuse Pontine Glioma. <i>Neurosurgery</i> , 1997, 40, 331-338.	1.1	44
39	Metastatic Low-Grade Gliomas in Children: 20 Years' Experience at St. Jude Children's Research Hospital. <i>Pediatric Blood and Cancer</i> , 2016, 63, 62-70.	1.5	42
40	Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. <i>Acta Neuropathologica</i> , 2016, 131, 299-307.	7.7	38
41	Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma. <i>Cancer</i> , 2006, 106, 1364-1371.	4.1	36
42	Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27035.	1.5	36
43	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. <i>Clinical Cancer Research</i> , 2021, 27, 2879-2889.	7.0	35
44	Past, Present, and Future Strategies in the Treatment of High-Grade Glioma in Children. <i>Cancer Investigation</i> , 2006, 24, 77-81.	1.3	34
45	Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG. <i>Acta Neuropathologica Communications</i> , 2020, 8, 57.	5.2	32
46	TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 637146.	4.8	32
47	Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas. <i>Frontiers in Oncology</i> , 2014, 4, 67.	2.8	31
48	Irradiation of Pediatric High-Grade Spinal Cord Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1451-1456.	0.8	29
49	Cervicomedullary tumors in children. <i>Journal of Neurosurgery: Pediatrics</i> , 2015, 16, 357-366.	1.3	29
50	The spectrum of rare central nervous system (CNS) tumors with <i>EWSR1</i> -nonETS fusions: experience from three pediatric institutions with review of the literature. <i>Brain Pathology</i> , 2021, 31, 70-83.	4.1	29
51	Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. <i>Nature Communications</i> , 2021, 12, 4089.	12.8	27
52	Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory <i>BRAF</i> V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10004-10004.	1.6	27
53	Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. <i>Acta Neuropathologica</i> , 2018, 136, 315-326.	7.7	26
54	Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts. <i>Brain Pathology</i> , 2018, 28, 112-120.	4.1	26

#	ARTICLE	IF	CITATIONS
55	Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 2561-2566.	2.3	25
56	Bereaved Parents' Intentions and Suggestions about Research Autopsies in Children with Lethal Brain Tumors. <i>Journal of Pediatrics</i> , 2013, 163, 581-586.	1.8	25
57	Occult post-contrast signal enhancement in pediatric diffuse intrinsic pontine glioma is the MRI marker of angiogenesis?. <i>Neuroradiology</i> , 2014, 56, 405-412.	2.2	25
58	Children with minimal chance for cure: parent proxy of the child's health-related quality of life and the effect on parental physical and mental health during treatment. <i>Journal of Neuro-Oncology</i> , 2016, 129, 373-381.	2.9	23
59	Characterization, Treatment, and Outcome of Intracranial Neoplasms in the First 120 Days of Life. <i>Journal of Child Neurology</i> , 2011, 26, 988-994.	1.4	21
60	Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis. <i>CNS Oncology</i> , 2014, 3, 421-431.	3.0	21
61	Prospective evaluation of local control and late effects of conformal radiation therapy in children, adolescents, and young adults with high-grade glioma. <i>Neuro-Oncology</i> , 2014, 16, 1652-1660.	1.2	21
62	Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 960, 151-157.	2.3	21
63	Pubertal development and primary ovarian insufficiency in female survivors of embryonal brain tumors following risk-adapted craniospinal irradiation and adjuvant chemotherapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 329-334.	1.5	20
64	Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10537-10537.	1.6	20
65	¹¹ C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 163-170.	2.9	19
66	Evaluation of ¹¹ C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 312-319.	5.0	18
67	Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 362-371.	2.4	17
68	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600 mutant relapsed refractory low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10506-10506.	1.6	17
69	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. <i>Cancer Research</i> , 2019, 79, 4026-4041.	0.9	16
70	Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. <i>Nature Cancer</i> , 2022, 3, 629-648.	13.2	16
71	Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1116-1122.	3.3	15
72	Bone marrow transplantation for severe aplastic anemia secondary to temozolomide. <i>Journal of Neuro-Oncology</i> , 2009, 91, 237-239.	2.9	14

#	ARTICLE	IF	CITATIONS
73	Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 47-53.	0.8	14
74	Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. <i>Neuro-Oncology</i> , 2020, 22, 1696-1704.	1.2	14
75	Pharmacokinetics of Erlotinib for the Treatment of High-Grade Glioma in a Pediatric Patient with Cystic Fibrosis: Case Report and Review of the Literature. <i>Pharmacotherapy</i> , 2009, 29, 858-866.	2.6	13
76	Mortality in children with low-grade glioma or glioneuronal tumors: A single-institution study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26717.	1.5	13
77	A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26832.	1.5	13
78	Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma. <i>Cancers</i> , 2020, 12, 643.	3.7	13
79	Dabrafenib in pediatric patients with BRAF V600E-positive high-grade glioma (HGG).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10505-10505.	1.6	12
80	Rapid and fulminant leptomeningeal spread following radiotherapy in diffuse intrinsic pontine glioma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26416.	1.5	11
81	The seventh international RASopathies symposium: Pathways to a cure—expanding knowledge, enhancing research, and therapeutic discovery. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 1915-1927.	1.2	10
82	Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1180-1183.	1.5	9
83	Malignant Transformation of Low-Grade Gliomas in Children: Lessons Learned From Rare Medical Events. <i>Journal of Clinical Oncology</i> , 2015, 33, 978-979.	1.6	9
84	Characteristics of patients ≥ 10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	1.2	9
85	Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 450-458.	0.8	8
86	Defining Optimal Target Volumes of Conformal Radiation Therapy for Diffuse Intrinsic Pontine Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 838-847.	0.8	7
87	Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. <i>Neuro-Oncology</i> , 0, , .	1.2	7
88	Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib. <i>Clinical Neuroradiology</i> , 2018, 28, 393-400.	1.9	6
89	Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 829-838.	2.3	6
90	Improving long-term survival in diffuse intrinsic pontine glioma. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 647-658.	2.8	5

#	ARTICLE	IF	CITATIONS
91	First-in-pediatrics phase I study of crenolanib besylate (CP-868,596-26) administered during and after radiation therapy (RT) in newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG).. Journal of Clinical Oncology, 2014, 32, 10064-10064.	1.6	5
92	Radiation dose response of neurologic symptoms during conformal radiotherapy for diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2020, 147, 195-203.	2.9	5
93	Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. Neuro-Oncology Advances, 2021, 3, vtab179.	0.7	5
94	Incidental diagnosis of diffuse intrinsic pontine glioma in children. Pediatric Blood and Cancer, 2015, 62, 1081-1083.	1.5	4
95	Clinical Characteristics and Long-Term Outcomes of Movement Disorders in Childhood Thalamic Tumors. Pediatric Neurology, 2016, 65, 71-77.	2.1	4
96	[11C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence. Journal of Nuclear Medicine, 2021, , jnumed.120.261891.	5.0	4
97	Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors. Pediatric Blood and Cancer, 2013, 60, 1552-1556.	1.5	3
98	Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1295-1305.	0.8	3
99	Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome. Pediatric Blood and Cancer, 2018, 65, e27030.	1.5	3
100	Is Schimmelpenning Syndrome Associated with Intracranial Tumors? A Case Report. Pediatric Neurosurgery, 2019, 54, 201-206.	0.7	2
101	ED-27 * CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME IN MOVEMENT DISORDER IN CHILDHOOD THALAMIC TUMORS. Neuro-Oncology, 2014, 16, v71-v72.	1.2	0
102	DIPG-45. RADIATION DOSE RESPONSE OF NEUROLOGIC SYMPTOM IMPROVEMENT DURING RADIOTHERAPY FOR DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, i58-i58.	1.2	0
103	Chemotherapy of Pediatric High-Grade Gliomas. , 2018, , 557-568.		0
104	Pulmonary function after treatment for embryonal brain tumors on SJMB03 that included craniospinal irradiation.. Journal of Clinical Oncology, 2013, 31, 10021-10021.	1.6	0
105	Developmental pharmacokinetics of topotecan (TPT), a renally excreted drug, in infants and young children with brain tumors.. Journal of Clinical Oncology, 2015, 33, 10055-10055.	1.6	0
106	IMMU-06. Landscape of adaptive immunity of childhood brain cancers. Neuro-Oncology, 2022, 24, i82-i82.	1.2	0